Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor

被引：3

作者：

Stuart, Darrin D. ^{[1
]}

Shao, Wenlin ^{[1
]}

Mishina, Yuji ^{[1
]}

Feng, Yun ^{[1
]}

Caponigro, Giordano ^{[1
]}

Cooke, Vesselina G. ^{[1
]}

Rivera, Stacey ^{[1
]}

Shen, Fang ^{[1
]}

Korn, Joshua ^{[1
]}

Griner, Lesley A. Mathews ^{[1
]}

Nishiguchi, Giselle ^{[1
]}

Taft, Benjamin ^{[2
]}

Wan, Lifeng ^{[2
]}

Subramanian, Sharadha ^{[2
]}

Lou, Yan ^{[2
]}

Setti, Lina ^{[2
]}

Burger, Matthew ^{[1
]}

Tamez, Victor ^{[1
]}

Rico, Alice ^{[2
]}

Aversa, Robert ^{[1
]}

Tellew, John ^{[3
]}

Haling, Jacob R. ^{[3
]}

Polyakov, Valery ^{[2
]}

Lambert, Amy ^{[1
]}

Zang, Richard ^{[2
]}

Van Abbema, Ann ^{[2
]}

Hekmat-Nejad, Mohamad ^{[2
]}

Amiri, Payman ^{[2
]}

Singh, Mallika ^{[2
]}

Keen, Nicholas ^{[1
]}

Dillon, Michael P. ^{[2
]}

Lees, Emma ^{[1
]}

Sellers, William R. ^{[1
]}

Ramurthy, Savithri ^{[2
]}

机构：

[1] Novartis Inst Biomed Res, Cambridge, MA USA

[2] Novartis Inst Biomed Res, Emveryville, CA USA

[3] Novartis Res Fdn, Genom Inst, San Diego, CA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-DDT01-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

DDT01-04

引用

页数：2

共 50 条

[1] RAF inhibitor LXH254 effectively inhibits B-and-CRAF, but not ARAF
Monaco, Kelli-Ann
Delach, Scott
Fordjour, Paul
Parikh, Salonee
Feng, Yun
Jaskelioff, Mariela
Stuart, Darrin
Caponigro, Giordano
CANCER RESEARCH, 2019, 79 (13)
[2] A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat
Li, Rong
Ren, Meiping
Lu, Wei
Yuan, Yunhua
Li, Jian
Zhong, Wu
BIOMEDICAL CHROMATOGRAPHY, 2021, 35 (02)
[3] LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Monaco, Kelli-Ann
Delach, Scott
Yuan, Jing
Mishina, Yuji
Fordjour, Paul
Labrot, Emma
McKay, Daniel
Guo, Ribo
Higgins, Stacy
Wang, Hui Qin
Liang, Jinsheng
Bui, Karen
Green, John
Aspesi, Peter
Ambrose, Jessi
Mapa, Felipa
Griner, Lesley
Jaskelioff, Mariela
Fuller, John
Crawford, Kenneth
Pardee, Gwynn
Widger, Stephania
Hammerman, Peter S.
Engelman, Jeffrey A.
Stuart, Darrin D.
Cooke, Vesselina G.
Caponigro, Giordano
CLINICAL CANCER RESEARCH, 2021, 27 (07) : 2061 - 2073
[4] Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics
Kozaki, Ryohei
Yasuhiro, Tomoko
Kato, Hikaru
Murai, Jun
Hotta, Shingo
Ariza, Yuko
Sakai, Shunsuke
Fujikawa, Ryu
Yoshida, Takao
PLOS BIOLOGY, 2023, 21 (03)
[5] AB801 is a highly potent and selective AXL kinase inhibitor that demonstrates significant anti-tumor activity
Paprcka, Susan Lee
Goshayeshi, Armon
Liu, Suan
Flores, Ruben
Rocha, Lauren
Leslie, Jhansi L.
Miles, Dillon H.
Foley, Corinne N.
Qu, Shiwei
Lamani, Manjunath
Paladugu, Srinivas
Huang, Hsin-Ting
Tribewal, Nidhi
Chen, Ada
Kulusich, Joseph
Garrido-Shaqfeh, Stefan
Fabila, Patricia
Jafri, Salema
Devarajan, Anuja
Fernandez-Salas, Ester
CANCER RESEARCH, 2023, 83 (07)
[6] Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics
Kozaki, Ryohei
Yasuhiro, Tomoko
Kato, Hikaru
Murai, Jun
Hotta, Shingo
Ariza, Yuko
Sakai, Shunsuke
Fujikawa, Ryu
Yoshida, Takao
PLOS ONE, 2023, 18 (03):
[7] Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor
Stuart, Darrin D.
Li, Nanxin
Poon, Daniel J.
Aardalen, Kimberly
Kaufman, Susan
Merritt, Hanne
Salangsang, Fernando
Lorenzana, Edward
Li, Allen
Ghoddusi, Majid
Caponigro, Giordano
Sun, Frank
Kulkarni, Swarupa
Kakar, Shefali
Turner, Nancy
Zang, Richard
Tellew, John
Pryer, Nancy
CANCER RESEARCH, 2012, 72
[8] A novel selective multi-targeted tyrosine kinase inhibitor with superior anti-tumor efficacy
Hjarnaa, P.
Fensholdt, Jef
INFLAMMATION RESEARCH, 2007, 56 : S464 - S465
[9] Pharmacological profile and anti-tumor properties of FHD-286: A novel BAF inhibitor for the treatment of transcription factor-driven cancers
Hentemann, Murphy
CANCER RESEARCH, 2022, 82 (12)
[10] Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Shao, Wenlin
Mishina, Yuji M.
Feng, Yun
Caponigro, Giordano
Cooke, Vesselina G.
Rivera, Stacy
Wang, Yingyun
Shen, Fang
Korn, Joshua M.
Griner, Lesley A. Mathews
Nishiguchi, Gisele
Rico, Alice
Tellew, John
Haling, Jacob R.
Aversa, Robert
Polyakov, Valery
Zang, Richard
Hekmat-Nejad, Mohammad
Amiri, Payman
Singh, Mallika
Keen, Nicholas
Dillon, Michael P.
Lees, Emma
Ramurthy, Savithri
Sellers, William R.
Stuart, Darrin D.
CANCER RESEARCH, 2018, 78 (06) : 1537 - 1548

← 1 2 3 4 5 →